BRPI0509326A - regime de dose múltiplo-variável para tratar distúrbios relacionados a tnf(alfa) - Google Patents

regime de dose múltiplo-variável para tratar distúrbios relacionados a tnf(alfa)

Info

Publication number
BRPI0509326A
BRPI0509326A BRPI0509326-0A BRPI0509326A BRPI0509326A BR PI0509326 A BRPI0509326 A BR PI0509326A BR PI0509326 A BRPI0509326 A BR PI0509326A BR PI0509326 A BRPI0509326 A BR PI0509326A
Authority
BR
Brazil
Prior art keywords
related disorders
dose
tnf
alpha
administration
Prior art date
Application number
BRPI0509326-0A
Other languages
English (en)
Inventor
Rebecca S Hoffman
Elliot Chartash
Lori K Taylor
George Richard Granneman
Philip Yan
Original Assignee
Abbott Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35006312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0509326(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Biotech Ltd filed Critical Abbott Biotech Ltd
Publication of BRPI0509326A publication Critical patent/BRPI0509326A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"REGIME DE DOSE MúLTIPLO-VARIáVEL PARA TRATAR DISTúRBIOS RELACIONADOS A TNF<244> São descritos métodos de dose múltiplo-variável para tratar distúrbios relacionados a TNFa, incluindo doença de Crohn e psoríase, compreendendo administrar inibidores de TNF<244>, incluindo anticorpos de TNFa. Métodos de dose múltiplo-variável incluem a administração de um inibidor de TNF em uma fase de indução ou carga seguida pela administração do agente em uma fase de manutenção ou tratamento, em que o inibidor de TNF é administrado em uma dosagem maior durante a fase de indução.
BRPI0509326-0A 2004-04-09 2005-04-11 regime de dose múltiplo-variável para tratar distúrbios relacionados a tnf(alfa) BRPI0509326A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56113904P 2004-04-09 2004-04-09
US56171004P 2004-04-12 2004-04-12
US56910004P 2004-05-07 2004-05-07
PCT/US2005/012007 WO2005110452A2 (en) 2004-04-09 2005-04-11 MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFα-RELATED DISORDERS

Publications (1)

Publication Number Publication Date
BRPI0509326A true BRPI0509326A (pt) 2007-09-04

Family

ID=35006312

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509326-0A BRPI0509326A (pt) 2004-04-09 2005-04-11 regime de dose múltiplo-variável para tratar distúrbios relacionados a tnf(alfa)

Country Status (22)

Country Link
US (16) US8889136B2 (pt)
EP (4) EP2338516A3 (pt)
JP (5) JP5748317B2 (pt)
KR (8) KR20180094148A (pt)
CN (5) CN103251945A (pt)
AU (1) AU2005244261B2 (pt)
BR (1) BRPI0509326A (pt)
CA (4) CA2847331A1 (pt)
CY (1) CY1118564T1 (pt)
DK (1) DK1737491T3 (pt)
ES (1) ES2611286T3 (pt)
HK (1) HK1104454A1 (pt)
HU (1) HUE031558T2 (pt)
IL (3) IL178430A (pt)
LT (1) LT1737491T (pt)
MX (1) MXPA06011677A (pt)
NZ (3) NZ579302A (pt)
PL (1) PL1737491T3 (pt)
PT (1) PT1737491T (pt)
TW (4) TW201705980A (pt)
WO (1) WO2005110452A2 (pt)
ZA (1) ZA200608097B (pt)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DK0929578T3 (da) * 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
US7115557B2 (en) * 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
EP2298810A3 (en) * 2002-07-19 2011-08-03 Abbott Biotechnology Ltd Treatment of TNF alpha related disorders
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
US20060083741A1 (en) * 2004-10-08 2006-04-20 Hoffman Rebecca S Treatment of respiratory syncytial virus (RSV) infection
DK1836665T3 (da) 2004-11-19 2013-04-15 Glaxosmithkline Llc Fremgangsmåde til specialtilpasset afgivelse af medikamentkombinationsprodukter med variabel dosis til individualisering af terapier
CA2903138A1 (en) 2005-05-16 2006-11-23 Abbvie Biotechnology Ltd. Use of tnfa inhibitor for treatment of erosive polyarthritis
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
EP1948235B1 (en) * 2005-11-01 2013-08-28 AbbVie Biotechnology Ltd Methods for determining efficacy of adalimumab in subjects having ankylosing spondylitis using ctx-ii and mmp3 as biomarkers
CA2641513C (en) 2006-02-28 2021-09-21 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
WO2007100763A2 (en) * 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
KR20080104343A (ko) * 2006-03-03 2008-12-02 엘란 파마슈티칼스, 인크. 나탈리주마브로 염증 및 자가면역 질환을 치료하는 방법
WO2007118084A2 (en) * 2006-04-03 2007-10-18 Stowers Institute For Medical Research Compositions and methods for treating polycystic kidney disease
SG170837A1 (en) * 2006-04-05 2011-05-30 Abbott Biotech Ltd Antibody purification
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
EP2666479A3 (en) 2006-04-10 2014-03-26 Abbott Biotechnology Ltd Uses and compositions for treatment of juvenile rheumatoid arthritis
EP2012586A4 (en) 2006-04-10 2010-08-18 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS
EP2007426A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
CA2564435A1 (en) * 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
EP2012824A4 (en) * 2006-04-10 2010-06-16 Abbott Biotech Ltd USE AND COMPOSITIONS FOR THE TREATMENT OF PSORIASIS
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20080311043A1 (en) * 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
EP2043711A4 (en) 2006-06-30 2017-08-30 AbbVie Biotechnology Ltd Automatic injection device
US20100093829A1 (en) * 2006-07-07 2010-04-15 Gorman James R Methods for preventing, postponing or improving the outcome of spinal device and fusion procedures
EP2684895A1 (en) 2006-10-27 2014-01-15 AbbVie Biotechnology Ltd Crystalline anti-hTNFalpha antibodies
JP2010513245A (ja) * 2006-12-14 2010-04-30 アクトジェニックス・エヌブイ 免疫調節を誘起するための結合分子の送達
WO2008147869A2 (en) * 2007-05-22 2008-12-04 Centocor, Inc. Markers and methods for assessing and treating crohn's disease and related disorders
US8092998B2 (en) * 2007-05-31 2012-01-10 Abbott Laboratories Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
CN101848733A (zh) * 2007-07-13 2010-09-29 艾博特生物技术有限公司 用于肺部给予TNFα抑制剂的方法和组合物
WO2009020654A1 (en) 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
EP2725035A1 (en) * 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
US8647626B2 (en) 2007-10-02 2014-02-11 Avaxia Biologics, Incorporated Compositions comprising TNF-specific antibodies for oral delivery
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
NZ602498A (en) 2007-11-30 2014-08-29 Abbvie Inc Protein formulations and methods of making same
SI2235059T1 (sl) 2007-12-26 2015-06-30 Xencor, Inc. Fc variante s spremenjeno vezjo na fcrn
WO2009086550A1 (en) * 2008-01-03 2009-07-09 Abbott Laboratories Predicting long-term efficacy of a compound in the treatment of psoriasis
NZ586828A (en) 2008-01-15 2012-12-21 Abbott Gmbh & Co Kg Powdered antibody compositions and methods of making same
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
CA2758964A1 (en) * 2009-04-16 2010-10-21 Abbott Biotherapeutics Corp. Anti-tnf-.alpha. antibodies and their uses
MX2011011541A (es) 2009-04-29 2012-02-28 Abbott Biotech Ltd Dispositivo de inyeccion automatico.
WO2011075524A1 (en) * 2009-12-15 2011-06-23 Abbott Biotechnology Ltd Improved firing button for automatic injection device
US20110150891A1 (en) * 2009-12-16 2011-06-23 Philip Bosch Methods of Treating Interstitial Cystitis
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
AU2011203815B2 (en) 2010-01-11 2015-11-26 Biogen Ma Inc. Assay for JC virus antibodies
RU2012147249A (ru) * 2010-04-07 2014-05-20 Эббви Инк. TNF-α- СВЯЗЫВАЮЩИЕ БЕЛКИ
WO2011146727A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
LT2575884T (lt) * 2010-06-03 2018-09-25 Abbvie Biotechnology Ltd Panaudojimai ir kompozicijos, skirti pūlingo hidradenito (hs) gydymui
WO2012050944A2 (en) * 2010-09-29 2012-04-19 Philip Bosch Methods of treating chronic prostatitis/chronic pelvic pain syndrome
US9717791B2 (en) 2010-10-08 2017-08-01 Novartis Ag Methods of treating psoriasis using IL-17 antibody
TWI603739B (zh) 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
BR112013018905B1 (pt) 2011-01-24 2021-07-13 Abbvie Biotechnology Ltd Dispositivos de injeção automática que têm superfícies de pega sobremoldadas.
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US20140065164A1 (en) 2011-04-29 2014-03-06 Bristol-Myers Squibb Company Ip-10 antibody dosage escalation regimens
US20140017174A1 (en) 2011-11-30 2014-01-16 Raja Atreya Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
US20150119329A1 (en) * 2012-04-16 2015-04-30 New York University Modulation of angiotensin ii receptors for the prevention and treatment of malaria cerebral
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
RS56093B1 (sr) * 2012-09-19 2017-10-31 Abbvie Biotherapeutics Inc Postupci za identifikovanje antitela sa smanjenom imunogenošću
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014193804A1 (en) 2013-05-28 2014-12-04 Biogen Idec Ma Inc. Method of assessing risk of pml
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
JP6526025B2 (ja) 2013-10-16 2019-06-05 オンコバイオロジクス，インコーポレイティド 抗体安定性を増強する緩衝液製剤
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015198320A1 (en) 2014-06-24 2015-12-30 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
WO2016103093A1 (en) 2014-12-23 2016-06-30 Pfizer Inc. Stable aqueous antibody formulation for anti tnf alpha antibodies
US9452344B2 (en) * 2015-01-02 2016-09-27 William J Ritter Puck system
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
EA035638B1 (ru) 2015-03-31 2020-07-20 ВиЭйчСКВЕАРД ЛИМИТЕД Полипептиды
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
US10519207B2 (en) 2015-06-12 2019-12-31 Georgia State University Research Foundation, Inc. Compositions and methods for treating opioid tolerance
WO2017007994A1 (en) 2015-07-08 2017-01-12 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
US20170104172A1 (en) * 2015-10-12 2017-04-13 The Regents Of The University Of Michigan Organic Light Emitting Diode Having a Mixed Blocking Layer
CN109400709B (zh) * 2015-11-13 2021-03-23 广东医科大学 双功能抗体及其用途
GB201522394D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
AU2017207906B2 (en) 2016-01-15 2021-03-11 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
AU2017213775A1 (en) 2016-02-03 2018-08-16 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
WO2017139065A1 (en) 2016-02-08 2017-08-17 American Gene Technologies International Inc. Hiv vaccination and immunotherapy
JP6741773B2 (ja) * 2016-03-08 2020-08-19 メレオ バイオファーマ １ リミテッド 炎症状態の急性増悪の治療のための投与レジメン
JP6741774B2 (ja) 2016-03-08 2020-08-19 メレオ バイオファーマ １ リミテッド 慢性閉塞性肺疾患の急性増悪の治療のための投与レジメン
US10767183B2 (en) 2016-03-09 2020-09-08 American Gene Technologies International Inc. Combination vectors and methods for treating cancer
US11976292B2 (en) 2016-06-08 2024-05-07 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
CA3028982A1 (en) 2016-07-08 2018-01-11 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
JP7176756B2 (ja) 2016-07-21 2022-11-22 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド パーキンソン病を処置するためのウイルスベクター
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions
CA3057142A1 (en) 2017-04-03 2018-10-11 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
US20200188482A1 (en) * 2017-04-28 2020-06-18 The Brigham And Women`S Hospital, Inc. Targeting gamma-delta t cells in obesity and cachexia
KR20190024572A (ko) * 2017-08-30 2019-03-08 (주)셀트리온 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
DE102017215154A1 (de) 2017-08-30 2019-02-28 Markus Bläss Zusammensetzung zur topischen Behandlung von nicht-Mikroorganismus-verursachten entzündlichen Haut- und Schleimhauterkrankungen
DK3585383T3 (da) 2017-12-11 2021-04-19 Mereo Biopharma 1 Ltd Anvendelse af 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamid i forebyggelsen af akutte forværringer af kronisk obstruktiv lungesygdom
AU2018382895B2 (en) 2017-12-11 2024-05-16 Mereo Biopharma 1 Limited Use of 3-(5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease
KR101982667B1 (ko) 2018-12-24 2019-05-27 가톨릭대학교 산학협력단 신규한 유도체를 유효성분으로 포함하는 tnf-관련 질환 예방 또는 치료용 조성물 및 이를 이용한 tnf 활성 억제 방법
AR118191A1 (es) * 2019-02-28 2021-09-22 Celltrion Inc MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa
US20220389092A1 (en) * 2019-04-05 2022-12-08 The Regents Of The University Of California Methods and compositions involving chimeric binding polypeptides
CN114466864A (zh) 2019-06-21 2022-05-10 索瑞索制药公司 多肽
CN114514243A (zh) 2019-06-21 2022-05-17 索瑞索制药公司 多肽
WO2021096199A1 (ko) * 2019-11-11 2021-05-20 에스케이케미칼 주식회사 피리메타민을 유효성분으로 포함하는 면역 관련 질환의 치료 또는 예방용 약학 조성물
EP4096647A1 (en) 2020-01-30 2022-12-07 Yeda Research and Development Co. Ltd Treating acute liver disease with tlr-mik inhibitors
EP4180423A1 (en) 2020-07-07 2023-05-17 ILAb Co., Ltd. Novel tnf activity inhibitor compound, and pharmaceutically acceptable salt thereof

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2859205A (en) * 1954-08-06 1958-11-04 Monsanto Chemicals Process of making styrenated phenolformaldehyde resins
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
CA1208546A (en) 1981-09-08 1986-07-29 Anthony Cerami Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
IL73883A (en) 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
EP0212489B1 (en) 1985-08-16 1994-11-30 The Rockefeller University Anabolic activity modulator and uses thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
EP0230574A3 (en) 1986-01-31 1989-03-22 Yale University Pharmaceutical compositions against infections caused by lav/htlv iii virus and the use thereof
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
JP2638652B2 (ja) 1988-07-18 1997-08-06 カイロン・コーポレーション カケクチンと反応するモノクロナール抗体
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68914244T2 (de) 1988-10-24 1994-10-27 Otsuka Pharma Co Ltd Monoklonaler Antikörper.
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
EP0374510B1 (en) 1988-12-19 1997-01-15 American Cyanamid Company Products for the treatment of endotoxic shock in a mammal
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
CA2003981C (en) 1988-12-27 2000-06-13 Hiroshi Ishimaru Pharmaceutical compositions and use thereof in the treatment of psoriasis
CA2064915C (en) 1989-08-07 2001-05-29 Deborah A. Rathjen Tumour necrosis factor binding ligands
CA2485553A1 (en) 1989-09-05 1991-03-21 Immunex Corporation Tumor necrosis factor - .alpha. and - .beta. receptors
GB8921123D0 (en) 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE4037604A1 (de) 1990-04-25 1991-10-31 Bayer Ag Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB2279077B (en) 1990-12-21 1995-06-14 Celltech Ltd Therapeutic compositions comprising recombinant antibodies specific for the TNFalpha
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5994510A (en) 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
CA2105300C (en) 1991-03-01 2008-12-23 Robert C. Ladner Process for the development of binding mini-proteins
WO1992016221A1 (en) 1991-03-15 1992-10-01 Synergen, Inc. Pegylation of polypeptides
US20070298040A1 (en) 1991-03-18 2007-12-27 Centocor, Inc. Methods of treating seronegative arthropathy with anti-TNF antibodies
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US20040120952A1 (en) 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
US20060246073A1 (en) 1991-03-18 2006-11-02 Knight David M Anti-TNF antibodies and peptides of human tumor necrosis factor
EP0610201B2 (en) 1991-03-18 2007-09-26 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
JPH06508502A (ja) 1991-03-29 1994-09-29 イミュネックス・コーポレーション 単離されたウイルス蛋白質サイトカイン拮抗薬
JP3672306B2 (ja) 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート ファージミドを使用するヘテロ二量体受容体ライブラリー
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
WO1993011793A1 (en) 1991-12-17 1993-06-24 Schering Corporation Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
US5605923A (en) 1992-04-02 1997-02-25 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
EP0585705B1 (en) 1992-08-28 1998-11-04 Bayer Corporation Use of monoclonal antibodies to TNF to treat bacterial meningitis
CA2123593C (en) 1992-09-15 2000-03-14 Craig A. Smith Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
AU682156B2 (en) 1992-10-15 1997-09-25 Dana-Farber Cancer Institute, Inc. Treatment of insulin resistance in obesity linked type II diabetes using antagonists to TNF-alpha function
PT614984E (pt) 1993-03-05 2001-12-28 Bayer Ag Anticorpos humanos anti-tnf
DE4307508A1 (de) 1993-03-10 1994-09-15 Knoll Ag Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Herzinsuffizienz (Herzmuskelschwäche)
RU2139092C1 (ru) 1993-06-03 1999-10-10 Терапьютик Антибодиз Инк. Фрагменты антител в терапии
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
NZ278607A (en) 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
EP0748338A4 (en) 1994-03-04 2001-03-28 Merck & Co Inc IN VITRO MATURATION OF ANTIBODIES BY MEANS OF ALANINE 'SCANNING' MUTAGENESIS
CA2218522A1 (en) 1995-04-20 1996-10-24 The Kennedy Institute Of Rheumatology Multiple administrations of anti-tnf antibody
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
WO1998004281A1 (en) 1996-07-26 1998-02-05 Smithkline Beecham Corpration Improved method of treating immune cell mediated systemic diseases
ATE245152T1 (de) 1999-03-31 2003-08-15 Pfizer Prod Inc Dioxocyclopentylhydroxamsäure
JP2003503360A (ja) 1999-06-24 2003-01-28 ファルマシア コーポレイション 炎症性疾患の処置のための併用療法
US6627196B1 (en) 1999-08-27 2003-09-30 Genentech, Inc. Dosages for treatment with anti-ErbB2 antibodies
AU6875900A (en) 1999-09-08 2001-04-10 Chugai Seiyaku Kabushiki Kaisha Protein solution preparation and method of stabilizing the same
WO2001037874A2 (en) 1999-11-24 2001-05-31 Centocor, Inc. Treatment of psoriasis by using an antibody to tnf alpha
DE60137421D1 (de) * 2000-06-29 2009-03-05 Abbott Lab Antikörper mit zwei spezifizitäten und verfahren zur deren herstellung und verwendung
DE10034390C2 (de) 2000-07-14 2003-06-26 Eads Deutschland Gmbh Drucksensor und Verfahren zu seiner Herstellung, sowie Verbrennungskraftmaschine mit Drucksensor
US20050249735A1 (en) 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
US20060018907A1 (en) 2000-08-07 2006-01-26 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
IL156618A0 (en) 2000-12-28 2004-01-04 Altus Biologics Inc Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same
WO2002096461A1 (en) 2001-05-25 2002-12-05 Abbott Gmbh & Co. Kg Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030161828A1 (en) 2002-02-19 2003-08-28 Abbott Gmbh & Co. Kg Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040009172A1 (en) 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20090280065A1 (en) 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
EP2298810A3 (en) 2002-07-19 2011-08-03 Abbott Biotechnology Ltd Treatment of TNF alpha related disorders
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US7285256B2 (en) 2003-04-04 2007-10-23 Newmont Usa Limited Precious metal recovery using thiocyanate lixiviant
TW201705980A (zh) * 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US20060083741A1 (en) 2004-10-08 2006-04-20 Hoffman Rebecca S Treatment of respiratory syncytial virus (RSV) infection
CA2903138A1 (en) 2005-05-16 2006-11-23 Abbvie Biotechnology Ltd. Use of tnfa inhibitor for treatment of erosive polyarthritis
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
EP1948235B1 (en) 2005-11-01 2013-08-28 AbbVie Biotechnology Ltd Methods for determining efficacy of adalimumab in subjects having ankylosing spondylitis using ctx-ii and mmp3 as biomarkers
SG170837A1 (en) 2006-04-05 2011-05-30 Abbott Biotech Ltd Antibody purification
US20080118496A1 (en) 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US20090317399A1 (en) 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
EP2012586A4 (en) 2006-04-10 2010-08-18 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS
EP2007426A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20080311043A1 (en) 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
EP2043711A4 (en) 2006-06-30 2017-08-30 AbbVie Biotechnology Ltd Automatic injection device
TW201516149A (zh) 2006-09-13 2015-05-01 Abbvie Inc 細胞培養改良
EP2684895A1 (en) 2006-10-27 2014-01-15 AbbVie Biotechnology Ltd Crystalline anti-hTNFalpha antibodies
US8092998B2 (en) 2007-05-31 2012-01-10 Abbott Laboratories Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders
EP2152318A4 (en) 2007-06-01 2011-12-07 Abbott Biotech Ltd COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
CN101848733A (zh) 2007-07-13 2010-09-29 艾博特生物技术有限公司 用于肺部给予TNFα抑制剂的方法和组合物
WO2009020654A1 (en) 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
CA2696210A1 (en) 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions and methods comprising binding proteins for adalimumab
NZ602498A (en) 2007-11-30 2014-08-29 Abbvie Inc Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
WO2009086550A1 (en) 2008-01-03 2009-07-09 Abbott Laboratories Predicting long-term efficacy of a compound in the treatment of psoriasis
NZ600979A (en) 2008-01-15 2014-01-31 Abbott Lab Improved mammalian expression vectors and uses thereof
NZ586828A (en) 2008-01-15 2012-12-21 Abbott Gmbh & Co Kg Powdered antibody compositions and methods of making same
EP2271671A2 (en) 2008-03-24 2011-01-12 Abbott Biotechnology Ltd. Tnf-alpha inhibitors for treating bone loss
MX2011011541A (es) 2009-04-29 2012-02-28 Abbott Biotech Ltd Dispositivo de inyeccion automatico.
NZ595694A (en) 2009-05-04 2013-09-27 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
JP2013518590A (ja) 2010-02-02 2013-05-23 アボツト・バイオテクノロジー・リミテツド ＴＮＦ−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
LT2575884T (lt) 2010-06-03 2018-09-25 Abbvie Biotechnology Ltd Panaudojimai ir kompozicijos, skirti pūlingo hidradenito (hs) gydymui

Also Published As

Publication number Publication date
US9499615B2 (en) 2016-11-22
CA2847142A1 (en) 2005-09-26
US20170022271A1 (en) 2017-01-26
US9061005B2 (en) 2015-06-23
JP2016155801A (ja) 2016-09-01
JP6145434B2 (ja) 2017-06-14
EP2338516A2 (en) 2011-06-29
AU2005244261B2 (en) 2011-09-22
US20090304682A1 (en) 2009-12-10
TW201422239A (zh) 2014-06-16
TWI556829B (zh) 2016-11-11
PL1737491T3 (pl) 2017-05-31
EP1737491A2 (en) 2007-01-03
EP2335731A2 (en) 2011-06-22
CA2504868C (en) 2016-11-29
CA2847331A1 (en) 2005-09-26
HUE031558T2 (en) 2017-07-28
ES2611286T3 (es) 2017-05-08
JP2017197547A (ja) 2017-11-02
KR20130108477A (ko) 2013-10-02
JP2008502596A (ja) 2008-01-31
EP1737491A4 (en) 2008-06-04
KR20170036138A (ko) 2017-03-31
US8961973B2 (en) 2015-02-24
CN103251945A (zh) 2013-08-21
US20140248275A1 (en) 2014-09-04
KR20070012701A (ko) 2007-01-26
US20210347874A1 (en) 2021-11-11
US20210347875A1 (en) 2021-11-11
KR101378873B1 (ko) 2014-03-28
EP2335731A3 (en) 2011-10-26
ZA200608097B (en) 2008-04-30
KR20120137421A (ko) 2012-12-20
US9187559B2 (en) 2015-11-17
LT1737491T (lt) 2016-12-27
KR20170143008A (ko) 2017-12-28
DK1737491T3 (en) 2017-02-06
US20170044249A1 (en) 2017-02-16
CN105148273A (zh) 2015-12-16
IL240740A0 (en) 2015-10-29
CA2847142C (en) 2015-04-07
HK1104454A1 (zh) 2008-01-18
KR101636446B1 (ko) 2016-07-05
US20150175690A1 (en) 2015-06-25
MXPA06011677A (es) 2007-01-23
KR20180094148A (ko) 2018-08-22
ES2611286T8 (es) 2021-08-04
KR20160079933A (ko) 2016-07-06
KR101282801B1 (ko) 2013-07-15
TW201705980A (zh) 2017-02-16
NZ579302A (en) 2011-05-27
AU2005244261A1 (en) 2005-11-24
US20140248276A1 (en) 2014-09-04
US8961974B2 (en) 2015-02-24
EP2338516A3 (en) 2011-10-26
NZ549959A (en) 2010-05-28
US20200017580A1 (en) 2020-01-16
CN102614512A (zh) 2012-08-01
IL178430A0 (en) 2007-02-11
IL220192A (en) 2017-08-31
KR20190039349A (ko) 2019-04-10
JP2015013869A (ja) 2015-01-22
CA2504868A1 (en) 2005-09-26
US20140212430A1 (en) 2014-07-31
TW201206478A (en) 2012-02-16
IL220192A0 (en) 2012-07-31
CA2970891A1 (en) 2005-09-26
US20190055308A1 (en) 2019-02-21
NZ591362A (en) 2012-10-26
CN103203019A (zh) 2013-07-17
US20140255396A1 (en) 2014-09-11
TWI439284B (zh) 2014-06-01
JP2012046524A (ja) 2012-03-08
US20060009385A1 (en) 2006-01-12
IL178430A (en) 2015-09-24
EP1737491B1 (en) 2016-11-02
CN105106951A (zh) 2015-12-02
WO2005110452A2 (en) 2005-11-24
JP5748317B2 (ja) 2015-07-15
EP2335732A2 (en) 2011-06-22
EP2335732A3 (en) 2011-10-26
WO2005110452A3 (en) 2006-08-03
US8889136B2 (en) 2014-11-18
US20140248277A1 (en) 2014-09-04
US20160185849A1 (en) 2016-06-30
PT1737491T (pt) 2017-01-31
CY1118564T1 (el) 2017-07-12
US20130122011A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
BRPI0509326A (pt) regime de dose múltiplo-variável para tratar distúrbios relacionados a tnf(alfa)
MX2022015499A (es) Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.
Fuji et al. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS JV trial
WO2006102596A3 (en) Dosage regimen for the treatment of a traumatic brain injury with progesterone
BRPI0406667A (pt) Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg
WO2008039898A3 (en) Methods for the treatment of a traumatic central nervous system injury
EA201491460A1 (ru) ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα
WO2011146777A3 (en) Device and method for providing a synergistic combination of phototherapy and a non-light energy modality to the brain
MX337511B (es) Medicamentos y metodos para tratar cefaleas.
BR0309280A (pt) Terapia de combinação para o tratamento de câncer
NO20050528L (no) Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
EA200200324A1 (ru) Способы применения селективных ингибиторов обратного захвата серотонина быстрого запуска для лечения половой дисфункции
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
MX2010010334A (es) Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
AR052152A1 (es) Producto farmaceutico para el tratamiento preventivo y terapeutico de trastornos del sueno
AR119033A1 (es) Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa
DE602004016754D1 (de) Kombinationstherapie gegen krebserkrankungen mit azd2171 und zd1839
BR112022001814A2 (pt) Métodos de tratamento de câncer multifocal
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
Dalkiran et al. Phantom limb pain treated with duloxetine: a case series
CN108014294A (zh) 一种治疗卵巢肿瘤的中药配方
CN106668039A (zh) 一种治疗神经衰弱的药物组合物
CN106309475A (zh) 一种治静脉炎的外用配方
Rosas et al. TRATAMENTO MÉDICO DO LINFEDEMA DOS MEMBROS INFERIORS
Seering et al. Amputation Pain Management

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ABBVIE BIOTECHNOLOGY LTD. (BM)

B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B15W Others matters related to applications: legal action concerning application

Free format text: INPI-52400.054780/2016-74 ORIGEM: JUIZO DA 09A VF DO RIO DE JANEIRO PROCESSO NO00050845120164025101 ACAO ORDINARIA COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: ABBVIE BIOTECHNOLOGY LTD. REU: AGENCIA NACIONAL DE VIGILANCIA SANITARIA - ANVISA

B15N Others concerning applications: notification of judicial decision

Free format text: INPI-52400.054780/2016-74 SECAO: JUDICIARIA DO RIO DE JANEIRO 9A VARA FEDERAL/RJ PROCESSO NO0005084-51.2016.4.02.5101 AUTOR: ABBVIE BIOTECHNOLOGY LTDA REU: AGENCIA NACIONAL DE VIGILANCIA SANITARIA DECISAO: PRESENTES OS PRESSUPOSTOS CONTIDOS NO ART.273 DO CODIGO DE PROCESSO CIVIL, CONCEDO A ANTECIPACAO DE TUTELA PARA DETERMINAR QUE A ANVISA REMETA AO INPI OS AUTOS DOS PROCEDIMENTOS ADMINISTRATIVOS REFERENTES AOS PEDIDOS DE PATENTES PI9715284-6, PI0509326-0, PI0206289-5 E PI0709726-3, PARA FINS DE ANALISE E DECISAO QUANTO AOS REQUISITOS DE PATENTEABILIDADE, DEVENDO O INPI REALIZAR AS RESPECTIVAS PUBLICACOES NA REVISTA DA PROPRIEDADE INDUSTRIAL RELATIVAS AO AJUIZAMENTO DO PRESENTE FEITO.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15G Petition not considered as such [chapter 15.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]